A360
Key Takeaways✦ Atlas AI
01
The Supreme Court’s May 14 order temporarily preserves telehealth and mail access to mifepristone, providing immediate legal clarity for providers and pharmacies while litigation continues.
02
Justices Alito and Thomas dissented, signaling continued judicial divisions that make additional appeals and eventual full review by the Supreme Court likely.
03
An FDA safety review and ongoing federal litigation will shape whether the current dispensing model for mifepristone remains in place long term; stakeholders should monitor regulatory milestones.
Atlas AI
Supreme Court on May 14 paused contested limits on mifepristone, preserving mail and telehealth access while a legal challenge proceeds and providers await further rulings.
What the order does
The court issued an indefinite extension of a prior freeze on new restrictions that would have narrowed how mifepristone is dispensed. The action allows prescriptions by telehealth and delivery by mail to continue while the underlying litigation moves forward.
The stay follows earlier, temporary pauses issued by Justice Samuel Alito and responds to a 5th U.S. Circuit Court of Appeals ruling that would have required in-person dispensing. The justices did not at this time take up the full merits of the case.
Dissent, data and parties involved
Justices Samuel Alito and Clarence Thomas registered formal dissents, with Alito arguing the decision conflicts with deference to state abortion rules and Thomas citing a dormant federal mailing statute. The two called for tighter limits on how the drug is distributed.
Teleprescribing and mailing now make up more than 60% of abortion care in the U.S. health system, a statistic cited by advocates on both sides to underscore the scope of the ruling. Manufacturers Danco Laboratories and GenBioPro urged the high court to restore telehealth and postal access.
Legal background and regulatory review
The underlying lawsuit, filed by Louisiana, challenges Biden administration guidance that eased access to the drug, arguing state interests and Medicaid spending were harmed. The 5th Circuit had already moved to restrict distribution before the Supreme Court freezes went into effect.
The Food and Drug Administration is conducting a safety review of the drug's Risk Evaluation and Mitigation Strategy, and previously asked courts to delay final decisions until that review is complete. The agency said it will provide updates as the evaluation reaches key milestones.
Civil and industry groups filed numerous briefs, warning that the 5th Circuit decision could unsettle broader FDA authority and the national drug approval framework. Both public health organizations and state attorneys general weighed in, reflecting the case's wide legal and policy reach.
Advocates for reproductive rights welcomed the stay as short-term relief but warned that access is not guaranteed in the long term. Drugmakers and their allies urged dismissal of the challenge and reiterated confidence in mifepristone's safety profile.
The court returned the matter to the 5th Circuit rather than hearing the full dispute immediately, making another Supreme Court review likely. Observers say the case could return to the high court in coming months as litigation and administrative review proceed.
Implications include continued telehealth dispensation for patients and operational stability for pharmacies and clinicians in the near term, while regulators, manufacturers and states prepare for the next legal phases. Watch for the FDA's review milestones and any expedited appeals up the judicial ladder.
